BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36453633)

  • 21. Adjuvant radiation therapy improves survival in stage IIIA (N2) non-small cell lung cancer with persistent N2 disease after neoadjuvant chemotherapy.
    Komiya T; Takamori S; Wilding G
    Radiother Oncol; 2022 Nov; 176():234-238. PubMed ID: 36192229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.
    Iezzoni LI; Ngo LH; Li D; Roetzheim RG; Drews RE; McCarthy EP
    Arch Phys Med Rehabil; 2008 Apr; 89(4):595-601. PubMed ID: 18373987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.
    Behera M; Ragin C; Kim S; Pillai RN; Chen Z; Steuer CE; Saba NF; Belani CP; Khuri FR; Ramalingam SS; Owonikoko TK
    Cancer; 2016 Jan; 122(1):50-60. PubMed ID: 26441041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
    Brandt WS; Yan W; Zhou J; Tan KS; Montecalvo J; Park BJ; Adusumilli PS; Huang J; Bott MJ; Rusch VW; Molena D; Travis WD; Kris MG; Chaft JE; Jones DR
    J Thorac Cardiovasc Surg; 2019 Feb; 157(2):743-753.e3. PubMed ID: 30415902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
    Wang K; Eblan MJ; Deal AM; Lipner M; Zagar TM; Wang Y; Mavroidis P; Lee CB; Jensen BC; Rosenman JG; Socinski MA; Stinchcombe TE; Marks LB
    J Clin Oncol; 2017 May; 35(13):1387-1394. PubMed ID: 28113017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group.
    Johnstone DW; Byhardt RW; Ettinger D; Scott CB
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):365-9. PubMed ID: 12243809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modern Radiation Therapy and Cardiac Outcomes in Breast Cancer.
    Boero IJ; Paravati AJ; Triplett DP; Hwang L; Matsuno RK; Gillespie EF; Yashar CM; Moiseenko V; Einck JP; Mell LK; Parikh SA; Murphy JD
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):700-8. PubMed ID: 26972642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery.
    Salazar MC; Rosen JE; Wang Z; Arnold BN; Thomas DC; Herbst RS; Kim AW; Detterbeck FC; Blasberg JD; Boffa DJ
    JAMA Oncol; 2017 May; 3(5):610-619. PubMed ID: 28056112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant treatment for elderly patients with early-stage lung cancer treated with limited resection.
    Veluswamy RR; Mhango G; Bonomi M; Neugut AI; Hershman DL; Aldridge MD; Wisnivesky JP
    Ann Am Thorac Soc; 2013 Dec; 10(6):622-8. PubMed ID: 24024700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival following sublobar resection for early-stage non-small cell lung cancer with or without adjuvant external beam radiation therapy: a population-based study.
    Rineer J; Schreiber D; Katsoulakis E; Nabhani T; Han P; Lange C; Choi K; Rotman M
    Chest; 2010 Feb; 137(2):362-8. PubMed ID: 19749007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
    Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
    Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
    Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
    Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC.
    Bishnoi R; Shah C; Blaes A; Bian J; Hong YR
    Lung Cancer; 2020 Dec; 150():172-177. PubMed ID: 33186859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of clinical T4 stage superior sulcus non-small cell lung cancer: a propensity-matched analysis of the surveillance, epidemiology, and end results database.
    Wen J; Liu D; Chen D; Chen J; Xu X; Chen C; Zhang F; Duan S; Zhu R; Fan M; Chen Y
    Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30647107
    [No Abstract]   [Full Text] [Related]  

  • 35. Resectable non-small cell lung cancer Adjuvant chemotherapy: slightly longer survival.
    Prescrire Int; 2016 Dec; 25(177):299-301. PubMed ID: 30758927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
    Schilder RJ; Goldberg M; Millenson MM; Movsas B; Rogatko A; Rogers B; Langer CJ
    Lung Cancer; 2000 Jan; 27(1):37-45. PubMed ID: 10672782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study.
    Wisnivesky JP; Smith CB; Packer S; Strauss GM; Lurslurchachai L; Federman A; Halm EA
    BMJ; 2011 Jul; 343():d4013. PubMed ID: 21757436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
    Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S
    Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Goss G; Paszat L; Newman TE; Evans WK; Browman G
    Cancer Prev Control; 1998 Feb; 2(1):32-9. PubMed ID: 9765764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
    Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
    J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.